Commonwealth of Pennsylvania Public School Empls Retrmt SYS Decreases Stake in Edwards Lifesciences Co. (NYSE:EW)

Commonwealth of Pennsylvania Public School Empls Retrmt SYS lessened its stake in Edwards Lifesciences Co. (NYSE:EW) by 4.4% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 125,409 shares of the medical research company’s stock after selling 5,728 shares during the quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS’s holdings in Edwards Lifesciences were worth $9,284,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also made changes to their positions in the stock. FSA Wealth Management LLC acquired a new stake in shares of Edwards Lifesciences during the 3rd quarter worth about $30,000. Migdal Insurance & Financial Holdings Ltd. acquired a new stake in shares of Edwards Lifesciences during the 4th quarter worth about $30,000. Prospera Private Wealth LLC acquired a new position in Edwards Lifesciences during the third quarter worth approximately $32,000. Avior Wealth Management LLC increased its position in Edwards Lifesciences by 138.7% during the third quarter. Avior Wealth Management LLC now owns 530 shares of the medical research company’s stock worth $35,000 after buying an additional 308 shares during the period. Finally, Roble Belko & Company Inc acquired a new position in Edwards Lifesciences during the fourth quarter worth approximately $46,000. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Insiders Place Their Bets

In other Edwards Lifesciences news, VP Donald E. Bobo, Jr. sold 9,500 shares of the business’s stock in a transaction on Thursday, March 13th. The stock was sold at an average price of $67.96, for a total transaction of $645,620.00. Following the sale, the vice president now directly owns 46,936 shares in the company, valued at approximately $3,189,770.56. The trade was a 16.83 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Steven R. Loranger sold 5,739 shares of the business’s stock in a transaction on Friday, February 14th. The stock was sold at an average price of $76.42, for a total value of $438,574.38. Following the sale, the director now owns 60,372 shares in the company, valued at approximately $4,613,628.24. The trade was a 8.68 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 51,303 shares of company stock worth $3,715,776. 1.29% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

EW has been the topic of several research analyst reports. Barclays lifted their price target on Edwards Lifesciences from $88.00 to $90.00 and gave the stock an “overweight” rating in a research report on Thursday, February 13th. Piper Sandler lifted their price target on Edwards Lifesciences from $70.00 to $73.00 and gave the stock a “neutral” rating in a research report on Wednesday, February 12th. Wolfe Research lowered Edwards Lifesciences from a “hold” rating to a “strong sell” rating in a research report on Wednesday, February 12th. Bank of America raised Edwards Lifesciences from a “neutral” rating to a “buy” rating and lifted their price target for the stock from $82.00 to $90.00 in a research report on Monday, December 16th. Finally, Morgan Stanley lifted their price target on Edwards Lifesciences from $70.00 to $75.00 and gave the stock an “equal weight” rating in a research report on Wednesday, February 12th. One investment analyst has rated the stock with a sell rating, fourteen have assigned a hold rating and twelve have assigned a buy rating to the stock. According to data from MarketBeat, the company has an average rating of “Hold” and an average target price of $79.95.

Edwards Lifesciences Stock Down 0.7 %

Edwards Lifesciences stock opened at $70.46 on Friday. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.46 and a quick ratio of 2.89. Edwards Lifesciences Co. has a 1-year low of $58.93 and a 1-year high of $96.12. The company has a market cap of $41.42 billion, a PE ratio of 10.11, a price-to-earnings-growth ratio of 4.82 and a beta of 1.12. The stock’s 50 day moving average price is $71.42 and its 200 day moving average price is $70.36.

Edwards Lifesciences (NYSE:EW) last posted its earnings results on Tuesday, February 11th. The medical research company reported $0.59 EPS for the quarter, topping analysts’ consensus estimates of $0.55 by $0.04. Edwards Lifesciences had a return on equity of 19.40% and a net margin of 72.93%. On average, sell-side analysts predict that Edwards Lifesciences Co. will post 2.45 EPS for the current fiscal year.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.